# Open-label Study of Surufatinib in Japanese Patients

> **NCT05077384** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hutchmed** · enrollment: 36 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Non-hematologic Malignancy

## Interventions

- **DRUG:** Surufatinib

## Key facts

- **NCT ID:** NCT05077384
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-02
- **Primary completion:** 2024-09-06
- **Final completion:** 2025-01-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077384, "Open-label Study of Surufatinib in Japanese Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05077384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*